Research programme: pain therapeutics - DURECT Corporation

Drug Profile

Research programme: pain therapeutics - DURECT Corporation

Alternative Names: DUROS hydromorphone

Latest Information Update: 10 Jul 2007

Price : $50

At a glance

  • Originator DURECT Corporation
  • Class Morphinans
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Pain
  • Discontinued Cancer pain

Most Recent Events

  • 10 Jul 2007 Preclinical trials in Pain in USA (unspecified route)
  • 10 Jul 2007 Discontinued - Preclinical for Cancer pain in USA (Intrathecal)
  • 03 Feb 2005 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top